



CORPORATE PROFILE

A public corporation registered on the
TSX Venture Exchange under the symbol “**APO**”

OUR MISSION

Acasti Pharma is a Canadian-based biopharmaceutical dedicated in the research, development and commercialization of proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment.

Acasti develops first-in-class and best-in-class anti-dyslipidemic products for the prescription drugs (Rx), medical foods (MF) and over-the-counter (OTC) markets.

HIGHLIGHTS / STRATEGY

- ◆ To achieve regulatory submission and successfully develop CaPre™ through clinical Phase II;
- ◆ To achieve short-term revenues with Onemia™;
- ◆ To out-license Vectos™ and CaPre™ rights.

PRODUCT PIPELINE



Over the counter



Medical Food



Prescription drug

IP and DISCOVERIES

Parent company : **Neptune Technologies & Bioresources Inc.**

- ◆ **Exclusive worldwide license** from Neptune:
 - Ocean Extract® Proprietary extraction process
 - Composition of matter;
 - Method of use;

Patent portfolio expanded by Acasti.

MARKETS

Food - Drug - Mass - Club

Targeted Market > 50% US Population
Fixed Dose Combination,
Commercialization Strategic Partners

OTC

GP's, cardiologist, naturopath,
chiropractors

Targeted Market > 50% US Population
Telmed & e-commerce

MEDICAL FOOD


Doctor prescription

- > \$ 30B market
- \$ 25B Statins
- \$ 1B Lavoza


PRESCRIPTION DRUG

PROOF OF CONCEPT

Precursor Neptune Clinical Study



CaPre™ Pre-Clinical Study



Phase II clinical study

EXIT STRATEGY

Acasti is looking to partner for CaPre™ after Phase II and in the near future for Onemia™ and Vectos™

Precedent transactions:					
Year	Company	Company	Program	Stage	Transaction Value
2008	GSK	Sirtris Pharma	Resvaratrol/ Natural Extract	Phase I	\$720M
2008	Genzyme	Isis Pharmaceutical	Lipid lowering agent	Phase II	\$825M

FINANCIAL FIGURES

TSX-Venture Exchange • Symbol "APO"

- ♦ R & D Investment 2008 - 2010 : \$Cdn 4M
- ♦ Acasti Total Investment : \$Cdn 9,4M
- ♦ Cash on hand (Sept. 30, 2011) : \$Cdn 9,250M
- ♦ Shares outstanding: 71,031,138
- ♦ Stock price (Sept. 31, 2011): \$Cdn 1.17
- ♦ Market Capitalization: \$Cdn 80,165,333



Toll Free: 1-888-221-0915
+1 403 221.0915
info@howardgroupinc.com
www.howardgroupinc.com

Investor Relations

Xavier Harland x.harland@acastipharma.com

Neptune contact:

André Godin a.godin@neptunebiotech.com

MANAGEMENT AND BOARD OF DIRECTORS

MANAGEMENT

NAME	POSITION
Henri Harland, MBA	Chief Executive Officer
Tina Sampalis, MD, PhD	President
Harlan Waksal, MD	Executive Vice-President, Business & Scientific Affairs
Pierre Lemieux, PhD	Chief Operation Officer
Xavier Harland, CFA, FRM	Chief Financial Officer
Neptune Administration and Accounting departments support	

Head Office:

225 Promenade du Centropolis, Suite 210, Laval, (Québec) Canada H7T 0B3
Tel.: +1 450-686-4555 Fax: +1 450-686-2505

www.acastipharma.com - info@acastipharma.com

BOARD OF DIRECTORS

NAME	POSITION
Ronald Denis, MD	Chairman, NTB
Michel Chartrand	Chief of Surgery, Sacré-Cœur Hospital
Marc Lebel, PhD	President, Groupe PharmEssor
Martin Godbout, PhD	Président, Production Glaciel
Henri Harland, MBA	President, Hodran
	President & CEO, NTB

Financial Communication

Xavier Harland, Chief Financial Officer
x.harland@acastipharma.com

Scientific Communication

Dr. Tina Sampalis, President
t.sampalis@acastipharma.com